Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 6/20 | 0.45 |
| ▸ | CYSLTR1 | Q9Y271 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4767117 | 0.91 | KMT2A (0.42) | KDM4EALDH1A1GAASMN1; SMN2CYP1A2 | |
| SCHEMBL4768380 | 0.89 | CYSLTR2 (0.41) | CYSLTR2CYSLTR1KDM4EALDH1A1GAA | |
| SCHEMBL4768388 | 0.89 | CYSLTR2 (0.41) | CYSLTR2CYSLTR1KDM4EALDH1A1GAA | |
| SCHEMBL4764591 | 0.89 | ALDH1A1 (0.38) | KDM4EALDH1A1GAADRD2DRD4 | |
| Oxalic Acid SCHEMBL4770485 | 0.89 | ALDH1A1 (0.46) | CYSLTR2CYSLTR1KDM4EALDH1A1GAA | |
| Oxalic Acid SCHEMBL4770498 | 0.89 | ALDH1A1 (0.46) | CYSLTR2CYSLTR1KDM4EALDH1A1GAA | |
| SCHEMBL4768350 | 0.80 | RAB9A (0.41) | GAASMN1; SMN2CYP1A2CYP2C19KMT2A | |
| SCHEMBL4763615 | 0.80 | RAB9A (0.41) | GAASMN1; SMN2CYP1A2CYP2C19KMT2A | |
| Oxalic Acid SCHEMBL4764765 | 0.80 | MAPT (0.41) | KDM4EALDH1A1GAASMN1; SMN2CYP1A2 | |
| Oxalic Acid SCHEMBL4764768 | 0.80 | MAPT (0.41) | KDM4EALDH1A1GAASMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1020445-B1 | FUSED PYRIDINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-6875761-B2 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. (JP) | 2005-04-05 | — | — | US | disclosed |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. | 2004-10-14 | — | — | US | disclosed |
| US-6790844-B2 | MUSCLE RELAXANTS; ANTISEROTONINE AGENT | EISAI CO., LTD (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20020013460-A1 | Condensed pyridine compound | EISAI CO., LTD | 2002-01-31 | — | — | US | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013460-A1 | Condensed pyridine compound | MUSK, HTR1A, PAX3 | CYSLTR2 936/4885CYSLTR1 1124/4885KDM4E 1050/4885 |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | MUSK, HTR1A, RYR1 | CYSLTR2 956/4885CYSLTR1 1088/4885KDM4E 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.